Accera Completes Enrollment in Alzheimer’s Disease Treatment Phase 3 Clinical Trial

Accera Completes Enrollment in Alzheimer’s Disease Treatment Phase 3 Clinical Trial
Boulder, Colorado-based Accera has completed enrollment for its Phase 3 NOURISH AD clinical trial of AC-1204 for the treatment of mild to moderate Alzheimer's disease (AD). Top-line data should be reported later this year. AC-1204 is an orally administered therapy with the potential to improve dementia patients’ cognition and daily functioning. The treatment works by inducing a mild state of ketosis, thereby providing an alternative energy source to the brain. AC-1204 potentially has a number of favorable properties as a product candidate for dementia, including once-daily dosing, a low potential
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *